Celularity Inc
CELU · XNASCIK 1752828fmd_1MPY3S6GFFD9KB6Y6EE9FEN3ZHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Jun 30, 2026, 30 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | 14 | 21 | 18 | 23 | 54 | 27 |
| Cost of revenue | – | – | – | – | 16 | 15 | 20 |
| Gross profit | – | 9 | 12 | (2) | 7 | 39 | 6 |
| Research and development | – | 53 | 88 | 78 | 30 | 17 | 15 |
| Selling, general and administrative | – | 31 | 71 | 66 | 51 | 59 | 51 |
| Operating income | (2) | (152) | (109) | (26) | (192) | (38) | (61) |
| Interest and investment income | 4 | 2 | – | – | – | – | – |
| Other non-operating income (expense) | 8 | (61) | 9 | 40 | (4) | (20) | (30) |
| Income before taxes | 7 | (213) | (100) | 14 | (196) | (58) | (92) |
| Income tax expense | 1 | (5) | 0 | 0 | 0 | – | 0 |
| Net income from continuing operations | (1) | (152) | (109) | (26) | (192) | (38) | (61) |
| Net income | 6 | (208) | (100) | 14 | (196) | (58) | (92) |
| Net income to common shareholders | (0) | (4) | – | – | – | (58) | (92) |